Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eleclazine in Dofetilide-Induced QT Prolongation
NCT02365532Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eleclazine in long QT syndrome (LQTS), sponsored by Gilead Sciences. Started Feb 2015; status: completed.
02
Drugs
eleclazine
03
Conditions
long QT syndrome (LQTS)
Beyond the preview
Go deeper on NCT02365532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365532.